Management of type 2 diabetes in chronic kidney disease
The management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-03-01
|
| Series: | BMJ Open Diabetes Research & Care |
| Online Access: | https://drc.bmj.com/content/9/1/e002300.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846127832803049472 |
|---|---|
| author | Salim S Virani Sankar D Navaneethan Jefferson L Triozzi L Parker Gregg |
| author_facet | Salim S Virani Sankar D Navaneethan Jefferson L Triozzi L Parker Gregg |
| author_sort | Salim S Virani |
| collection | DOAJ |
| description | The management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon-like peptide-1 receptor agonists are second-line agents. The use of other antidiabetic agents should consider patient preferences, comorbidities, drug costs, and the risk of hypoglycemia. Renin–angiotensin–aldosterone system inhibitors are strongly recommended for patients with diabetes, hypertension, and albuminuria. Non-steroidal mineralocorticoid receptor antagonists, which pose less risk of hyperkalemia than steroidal agents, are undergoing further evaluation among patients with diabetic kidney disease. Here, we discuss important advancements in the management of patients with type 2 diabetes and CKD. |
| format | Article |
| id | doaj-art-a8d901e65415419dabb983f19e66912d |
| institution | Kabale University |
| issn | 2052-4897 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Diabetes Research & Care |
| spelling | doaj-art-a8d901e65415419dabb983f19e66912d2024-12-11T08:55:10ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972021-03-019110.1136/bmjdrc-2021-002300Management of type 2 diabetes in chronic kidney diseaseSalim S Virani0Sankar D Navaneethan1Jefferson L Triozzi2L Parker Gregg3Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety, Houston, Texas, USA1 Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USADepartment of Medicine, Baylor College of Medicine, Houston, Texas, USAVA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas, USAThe management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon-like peptide-1 receptor agonists are second-line agents. The use of other antidiabetic agents should consider patient preferences, comorbidities, drug costs, and the risk of hypoglycemia. Renin–angiotensin–aldosterone system inhibitors are strongly recommended for patients with diabetes, hypertension, and albuminuria. Non-steroidal mineralocorticoid receptor antagonists, which pose less risk of hyperkalemia than steroidal agents, are undergoing further evaluation among patients with diabetic kidney disease. Here, we discuss important advancements in the management of patients with type 2 diabetes and CKD.https://drc.bmj.com/content/9/1/e002300.full |
| spellingShingle | Salim S Virani Sankar D Navaneethan Jefferson L Triozzi L Parker Gregg Management of type 2 diabetes in chronic kidney disease BMJ Open Diabetes Research & Care |
| title | Management of type 2 diabetes in chronic kidney disease |
| title_full | Management of type 2 diabetes in chronic kidney disease |
| title_fullStr | Management of type 2 diabetes in chronic kidney disease |
| title_full_unstemmed | Management of type 2 diabetes in chronic kidney disease |
| title_short | Management of type 2 diabetes in chronic kidney disease |
| title_sort | management of type 2 diabetes in chronic kidney disease |
| url | https://drc.bmj.com/content/9/1/e002300.full |
| work_keys_str_mv | AT salimsvirani managementoftype2diabetesinchronickidneydisease AT sankardnavaneethan managementoftype2diabetesinchronickidneydisease AT jeffersonltriozzi managementoftype2diabetesinchronickidneydisease AT lparkergregg managementoftype2diabetesinchronickidneydisease |